辛妥珠单抗对非酒精性脂肪性肝炎所致桥接纤维化或代偿性肝硬化患者无效
两项2b期双盲试验分别纳入219例桥接纤维化和258例代偿性肝硬化患者,随机给予辛妥珠单抗或安慰剂。第96周时,辛妥珠单抗未显著降低肝胶原含量或肝静脉压力梯度,因无效而终止,不良事件发生率组间相似。
要点
- 桥接纤维化患者中,辛妥珠单抗75mg与安慰剂相比肝胶原含量变化差异无统计学意义(-0.2%,95%CI -1.3至1.0,P=0.77)。
- 代偿性肝硬化患者中,辛妥珠单抗200mg与安慰剂相比肝静脉压力梯度平均差异为0.1 mmHg(95%CI -1.2至1.5,P=0.84)。
- 辛妥珠单抗未显著改善纤维化分期、桥接纤维化进展至肝硬化或肝硬化患者的肝脏相关临床事件。
核心结论
- 在两项2b期试验中,辛妥珠单抗对非酒精性脂肪性肝炎相关的桥接纤维化或代偿性肝硬化患者无效,未能分别降低肝胶原含量或肝静脉压力梯度。
研究设计与样本
- 两项双盲2b期试验:219例桥接纤维化患者按1:1:1随机接受每周皮下注射辛妥珠单抗75mg、125mg或安慰剂,计划疗程240周;258例代偿性肝硬化患者按1:1:1随机接受每两周静脉输注辛妥珠单抗200mg、700mg或安慰剂;2013年1月至2014年7月在北美和欧洲80个中心进行。
主要发现
- 桥接纤维化患者中,辛妥珠单抗75mg组与安慰剂组肝胶原含量变化差异无统计学意义(-0.2%,95%CI -1.3至1.0,P=0.77),125mg组与安慰剂组差异也无统计学意义(-0.4%,95%CI -1.5至0.8,P=0.52)。
- 代偿性肝硬化患者中,辛妥珠单抗200mg组与安慰剂组肝静脉压力梯度平均差异为0.1 mmHg(95%CI -1.2至1.5,P=0.84),700mg组与安慰剂组平均差异为0.1 mmHg(95%CI -1.2至1.4,P=0.88)。
- 辛妥珠单抗未显著降低纤维化分期、桥接纤维化患者进展至肝硬化的比例或肝硬化患者的肝脏相关临床事件。
- 不良事件发生率各组相似。
局限性
- 两项研究因缺乏疗效在第96周后终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Lysyl oxidase-like 2 contributes to fibrogenesis by catalyzing cross-linkage of collagen. We evaluated the safety and efficacy of simtuzumab, a monoclonal antibody against lysyl oxidase-like 2, in two phase 2b trials of patients with advanced fibrosis caused by nonalcoholic steatohepatitis. METHODS: We performed a double-blind study of 219 patients with bridging fibrosis caused by nonalcoholic steatohepatitis who were randomly assigned (1:1:1) to groups given weekly subcutaneous injections of simtuzumab (75 or 125 mg) or placebo for a planned duration of 240 weeks. We performed a separate study of 258 patients with compensated cirrhosis randomly assigned (1:1:1) to groups given intravenous infusions of simtuzumab (200 or 700 mg) or placebo every other week. The studies were performed from January 2013 through July 2014 at 80 sites in North America and Europe. Biopsy specimens were collected and analyzed at screening and at weeks 48 and 96; clinical information and serum levels of fibrosis biomarkers were collected throughout the study. The primary end point was change from baseline to week 96 in hepatic collagen content, measured by morphometry of liver specimens, in patients with bridging fibrosis; for patients with cirrhosis, the primary end point was change in hepatic venous pressure gradient from baseline to week 96. RESULTS: The 2 studies were stopped after week 96 because of lack of efficacy. All 3 groups of patients with bridging fibrosis-including those given placebo-had significant decreases in hepatic collagen content, but there was no statistically significant difference in decrease between patients receiving simtuzumab 75 mg and those receiving placebo (-0.2%, 95% confidence interval [CI] -1.3 to 1.0, P = .77) or between patients receiving simtuzumab 125 mg and those receiving placebo (-0.4%, 95% CI -1.5 to 0.8, P = .52). In patients with cirrhosis, the mean difference in hepatic venous pressure gradient between the 2 simtuzumab groups and the placebo group was 0.1 mm Hg (95% CI -1.2 to 1.5, P = .84 for 200 mg; 95% CI -1.2 to 1.4, P = .88 for 700 mg). Simtuzumab did not significantly decrease fibrosis stage, progression to cirrhosis in patients with bridging fibrosis, or liver-related clinical events in patients with cirrhosis. Rates of adverse events were similar among groups. CONCLUSION: In two phase 2b trials of patients with bridging fibrosis or compensated cirrhosis associated with nonalcoholic steatohepatitis, simtuzumab was ineffective in decreasing hepatic collagen content or hepatic venous pressure gradient, respectively. Clinicaltrials.govNCT01672866 and NCT01672879.
引用
- Harrison SA, Abdelmalek MF, Caldwell S, et al. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. Gastroenterology. 2018. PMID: 29990488. doi:10.1053/j.gastro.2018.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。